---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000061"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-08-06T20:10:29+00:00"
generated_at: "2026-08-06T20:13:57.132516+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis Q2 2026 cash $174.6M; DENALI Part 2 topline readout expected 1H 2027

## Summary
- Cash, cash equivalents and marketable securities of $174.6M as of June 30, 2026, providing runway into late 2027.
- R&D expenses $35.2M (up $7.6M YoY) driven by $7.0M milestone payment for ASPENOVA Phase 3 start and increased clinical costs.
- Total operating expenses $44.4M for Q2 2026 vs $36.1M in Q2 2025.
- FDA Type D meeting: no objection to azenosertib 400mg QD 5:2 dose for Cyclin E1-positive PROC; accelerated approval strategy intact.
- DENALI Part 2 enrollment complete in Parts 2a/2b; Part 2c enrolling; integrated topline readout expected 1H 2027.

## SEC filing metadata
- accession: 0001725160-26-000061
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-08-06T20:10:29+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/0001725160-26-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/zntl-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000061
- JSON: https://secwatch.observer/filing/0001725160-26-000061.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.